Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




"Super-Healing” Mice Helping to Understand Post-Traumatic Arthritis

By HospiMedica International staff writers
Posted on 09 Mar 2009
A new strain of laboratory mice that resists inflammation following a knee injury and avoids developing arthritis in the long term could aid the development of new therapies for treating posttraumatic Arthritis. More...


Researchers from Duke University (Durham, NC, USA) examined the differences in inflammatory response between two types of mice; one type known as "superhealers” (MRL/MpJ) versus a strain of control mice (C57BL/6), by examining cytokine--signaling molecules produced by cells in response to injury that promote inflammation and an increase in temperature--levels. The control mice showed a greater than 700-fold increase in the expression of interleukin 1β (IL-1β) in the first four hours after a fracture, and 37-fold difference at seven days after the fracture.

The "superhealer” mice showed a similar trend, but in much lower amounts: a 70-fold peak in expression at day zero down to a 3.5-fold increase by day seven. A second cytokine, tumor-necrosis factor α (TNF-α), was also expressed at a significantly higher rate in the control mice after the fracture (from a 13-fold peak just after fracture to five-fold at seven days), while the superhealer mice showed no change in their levels of TNF-α at all over time. The researchers also studied the mice's synovial (joint) fluid and blood serum to measure actual levels of the cytokines; overall, the control mice again showed significantly higher serum levels and synovial fluid levels of cytokines compared with the superhealers. The study was presented at the Orthopedic Research Society meeting, held during February 2009 in Las Vegas (NV, USA).

"The superhealer can almost regenerate tissue,” said lead author Bridgette Furman, Ph.D., a research analyst at Duke. "We thought, ‘if they can regenerate cartilage in the ear, what about cartilage in the knee?' This happened in our pilot study, and we now have taken these results further and learned what happens in terms of inflammation. If you can figure out why the animal is a superhealer and apply that to people, then you may help prevent the development of arthritis.”

In future studies the researchers plan to use rheumatoid arthritis drugs such as anakinra (an IL-1 receptor antagonist) and etanercept (a TNF blocker) in normal mice immediately after a fracture to find out if by inhibiting the inflammatory cytokines long-term arthritis could be prevented.

Related Links:

Duke University




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.